Onsite Women’s Health, Whiterabbit and Washington University in St. Louis join forces to explore breast density and implications for breast cancer risk
Nashville, TN— October 27, 2022— Onsite Women’s Health, a leading national provider of breast health services, announces with Whiterabbit.ai and Washington University in St. Louis the results of a longitudinal study of breast density using artificial intelligence (AI). RSNA (Radiological Society of North America) accepted the scientific abstract submitted by researchers from Onsite, Whiterabbit and Washington University in St. Louis for an oral presentation, titled: Artificial Intelligence and Consistency in Patient Care: A Large-Scale, Longitudinal Study of Breast Density Assessment at the 108th Scientific Assembly and Annual Meeting (Date/Time of Session: 11/28/2022 1:30-2:30 pm CT).
“Higher density breast tissue on mammograms means higher risk for breast cancer,” says Dr. Susan Holley, Clinical Director of Onsite Women’s Health and presenter of the abstract. “Therefore, breast density is an important variable to get right. We wanted to know if an AI tool could help us be right more often, over the long-term.”
“We are eager to share the findings of this large-scale retrospective study as it reveals fascinating trends about the assessment of breast density over time by radiologists and our AI software, WRDensity. We believe the consistent assessment of breast density is vital to more effective patient management that moves us towards the goal of precision medicine. I’m enthusiastic that new technologies may make a difference in this noble endeavor,” says Jason Su, Whiterabbit’s co-founder and CTO. “We are grateful to have been able to partner with Onsite and Washington University in St. Louis to conduct this study. Their interest in our AI tool and engagement with us has and will continue to be critical to its ongoing development.”
The team hopes to expand upon this work to explore implications for supplemental screening, and how longitudinal changes in breast density might further inform our understanding of breast cancer risk.
“The diversity of our research team with representation from real world practice, industry, and academic researchers allows us to pursue really exciting and clinically relevant questions,” concludes Aimilia Gastounioti, Assistant Professor of Radiology and Director of the Breast Image Computing Lab at Washington University in St. Louis. “The advent of AI is poised to change the delivery of health care dramatically in the near future. With academic researchers, physicians and industry partners working hand-in-hand, we can bring all our strengths together to look at questions that have big implications for breast imaging and patient care.”
About Onsite Women’s HealthOnsite Women’s Health is the leading provider of convenient breast health services, including 3D Tomosynthesis mammography screening and diagnostic services and screening breast ultrasound powered by an AI-driven strategy. Onsite partnerships support screening compliance by ensuring preventive breast care is convenient, accessible, and personalized to the individual risk profile of each patient. By utilizing advanced risk assessment tools, Onsite creates a personalized breast care plan for each patient applying the latest technology and expert review to each service. Onsite services increase patient satisfaction, improves breast health compliance, and serves as a revenue opportunity for our practice clients. They currently operate in 25 states with two more states being added soon. They have performed 1.5 million studies since 2013 and conducted 98,000 risk assessment exams since January 2018. For more information visit us at: www.onsitewomenshealth.com
Whiterabbit.ai is an AI technology company with a mission to improve lives through earlier, more accurate cancer detection. A growing number of radiologists and healthcare providers are using Whiterabbit’s technology to improve patients’ experience with breast cancer screening. In addition to ACT, an AI-powered outreach service that helps improve compliance and get more women screened, Whiterabbit has developed two other product lines – WRDensity and WRRisk. WRDensity is an FDA-cleared artificial intelligence-driven software that helps radiologists better assess breast density. WRRisk, a clinical decision support software for risk assessment based on well-established breast cancer risk models, assigns a risk rating to a patient and provides vital information to a physician to create a more personalized screening regimen with consistent follow-up and more accurate clinical diagnosis. Whiterabbit is headquartered in Santa Clara, California. For more about Whiterabbit, visit https://whiterabbit.ai/
About Washington University in St. Louis
The Washington University School of Medicine in St. Louis, consistently ranked in the top 10 medical schools in the United States by U.S. News & World Report and by funding from the National Institutes of Health (NIH), has a rich scientific history in basic, clinical, and translational research. The Breast Image Computing Lab at Washington University in St. Louis, led by Aimilia Gastounioti, conducts translational breast imaging research towards risk assessment, early diagnosis and prognosis for breast cancer. Their research activities combine elements of computational breast imaging, AI, and informatics to build technologies with a potential for clinical impact in advancing breast cancer screening and prevention strategies. For more information, visit us at https://mir.wustl.edu/gastounioti-lab